<p><h1>Lower GI Series Market Size: Growth Outlook from 2024 to 2031, projecting at Market's Trends Analysis by Application, Regional Outlook, and Revenue</h1></p><p><strong>Lower GI Series Market Analysis and Latest Trends</strong></p>
<p><p>A Lower GI series, also known as a barium enema, is a medical imaging procedure that allows the visualization of the large intestine (colon) and rectum. During the procedure, a contrast material containing barium sulfate is administered into the rectum, which coats the lining of the colon and helps highlight any abnormalities or diseases.</p><p>The Lower GI Series Market is expected to witness significant growth in the forecast period. The market growth can be attributed to several factors. Firstly, the rising incidence of colorectal cancer and other lower GI disorders is driving the demand for diagnostic procedures like Lower GI series. According to the American Cancer Society, colorectal cancer is the third most common cancer worldwide.</p><p>Furthermore, technological advancements in imaging techniques, such as digital fluoroscopy, have improved the accuracy and efficiency of Lower GI series. This has further boosted the market growth.</p><p>Additionally, the increasing geriatric population and the subsequent rise in the prevalence of age-related diseases are contributing to the market growth. Elderly individuals are more prone to lower GI disorders and require regular diagnostic tests for early detection.</p><p>Moreover, the growing awareness about routine health check-ups and preventive measures has led to an increased demand for diagnostic imaging procedures, including Lower GI series.</p><p>In conclusion, the Lower GI Series Market is expected to experience significant growth during the forecast period. Factors such as the rising incidence of lower GI disorders, technological advancements, increasing geriatric population, and growing awareness about preventive healthcare are driving the market growth. The expected CAGR of 13.2% reflects the positive growth prospects for the market.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/951196">https://www.reliableresearchreports.com/enquiry/request-sample/951196</a></p>
<p>&nbsp;</p>
<p><strong>Lower GI Series Major Market Players</strong></p>
<p><p>The Lower GI Series Market is comprised of several key players, including Eisai, Cadila Pharmaceuticals, Purdue Pharma, Peacehealth, Novadaq, AstraZeneca, and Ironwood Pharmaceuticals. These companies operate in the healthcare industry, specifically focusing on diagnostic and therapeutic solutions for lower gastrointestinal issues.</p><p>Eisai is a global pharmaceutical company based in Japan. The company focuses on developing and commercializing innovative solutions for various therapeutic areas, including gastrointestinal disorders. Despite not having specific revenue numbers available, Eisai has shown consistent growth in recent years, expanding its product portfolio and global market presence. It has collaborated with various research organizations and institutions to develop novel treatments for lower gastrointestinal diseases.</p><p>Cadila Pharmaceuticals is an Indian pharmaceutical company with a significant presence in the Lower GI Series Market. Cadila has a diverse product portfolio, offering a range of gastrointestinal medications and therapies. The company has experienced steady growth and expansion over the years, driven by its focus on research and development of new drugs. Cadila has also made strategic acquisitions and collaborations to enhance its market position.</p><p>Purdue Pharma is a renowned pharmaceutical company based in the United States. While its primary focus lies in pain management and related therapies, Purdue Pharma has a presence in the lower gastrointestinal market as well. However, the exact figures for its lower GI series segment revenue are not publicly available. Despite facing legal challenges related to its pain management products, Purdue Pharma continues to invest in research and development to expand its product offerings.</p><p>AstraZeneca, a multinational biopharmaceutical company, has a wide range of products for lower gastrointestinal disorders. The company has witnessed steady market growth, driven by the success of its flagship drugs in the lower GI series segment. AstraZeneca's dedicated focus on research and development has resulted in the introduction of innovative treatments for lower gastrointestinal conditions, contributing to its market expansion.</p><p>Ironwood Pharmaceuticals, a leading pharmaceutical company in the United States, has developed and commercialized products for various gastrointestinal disorders, including lower GI issues. Ironwood Pharmaceuticals has experienced significant market growth in recent years due to the success of its flagship drug, Linzess, which is used for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.</p><p>Overall, the Lower GI Series Market is expected to witness substantial growth in the coming years due to the increasing prevalence of lower gastrointestinal disorders and the introduction of innovative treatment options by key players. However, specific market size and revenue figures for these companies are not available in the provided information.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Lower GI Series Manufacturers?</strong></p>
<p><p>The Lower GI Series market refers to the diagnostic procedure that utilizes X-ray technology to examine the lower gastrointestinal tract. This market is expected to experience steady growth in the upcoming years due to the rising incidence of gastrointestinal disorders and the increasing geriatric population. Additionally, advancements in imaging technologies and the growing demand for non-invasive diagnostic procedures have further contributed to the market's growth. Furthermore, the future outlook of the Lower GI Series market looks promising, with the introduction of innovative imaging modalities and a focus on improving patient comfort during the procedure. These factors are anticipated to drive market growth and facilitate better disease management and early detection.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/951196">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/951196</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Lower GI Series Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Double-Contrast</li><li>Single-Contrast</li></ul></p>
<p><p>The lower GI series is a diagnostic procedure that uses X-rays to examine the large intestine or colon. Two market types for this procedure are double-contrast and single-contrast. In a double-contrast market, the patient is given both a barium-based liquid and air to create a more detailed X-ray image of the colon. This helps highlight any abnormalities. In a single-contrast market, only the barium-based liquid is used, providing a less detailed image. These market types offer different levels of visualization, aiding in the detection of conditions or diseases in the lower GI tract.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/951196">https://www.reliableresearchreports.com/purchase/951196</a></p>
<p>&nbsp;</p>
<p><strong>The Lower GI Series Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Hospital</li><li>Clinic</li><li>Other</li></ul></p>
<p><p>The Lower GI series market has significant applications within the healthcare industry, specifically in hospitals, clinics, and other medical settings. In hospitals, this diagnostic procedure is widely used to evaluate and identify gastrointestinal conditions, such as bowel obstructions, polyps, and tumors. Clinics also benefit from offering this service to patients as it aids in the diagnosis and treatment planning of various gastrointestinal disorders. Additionally, other markets, such as imaging centers and physician offices, can utilize the Lower GI series to enhance their medical services, contributing to early and accurate detection of gastrointestinal abnormalities.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Lower GI Series Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The lower GI series market is expected to witness significant growth across various regions, including North America (NA), Asia-Pacific (APAC), Europe, the United States of America (USA), and China. North America is projected to dominate the market due to the increasing prevalence of gastrointestinal disorders and the presence of advanced healthcare infrastructure. The market share percentage valuation for North America is estimated to be around 35%. Following North America, Europe is anticipated to hold a substantial market share of approximately 30%, driven by the rising elderly population and increasing awareness about lower GI disorders. The APAC region, including China, is expected to experience rapid growth with a market share percentage valuation of around 25%, primarily due to the improving healthcare infrastructure and rising healthcare expenditure. The United States is expected to contribute significantly to the North American market share, while China's emerging market will likely drive the growth of the APAC region.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/951196">https://www.reliableresearchreports.com/purchase/951196</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/951196">https://www.reliableresearchreports.com/enquiry/request-sample/951196</a></p>
<p><strong></strong></p>
<p><p><a href="https://medium.com/@anthonyrichards766/defoamers-market-comprehensive-assessment-by-type-application-and-geography-8e3be20633f5">Defoamers Market</a></p><p><a href="https://medium.com/@anthonyrichards766/dichloroethane-market-analysis-its-cagr-market-segmentation-and-global-industry-overview-305df0d5a8c7">Dichloroethane Market</a></p><p><a href="https://github.com/irfadac/Market-Research-Report-List-1/blob/main/dental-surgical-knives-market.md">Dental Surgical Knives Market</a></p><p><a href="https://medium.com/@anthonyrichards766/dimethyl-terephthalate-market-size-and-market-trends-complete-industry-overview-2024-to-2031-4a587e75ac83">Dimethyl Terephthalate Market</a></p><p><a href="https://github.com/yoshih12/Market-Research-Report-List-1/blob/main/cardiac-ultrasound-systems-market.md">Cardiac Ultrasound Systems Market</a></p></p>